First filing for GSK and HGS's Benlysta for lupus
This article was originally published in Scrip
GlaxoSmithKline and Human Genome Sciences' candidate for systemic lupus erythematosus (SLE), Benlysta (belimumab), has been filed in the EU, its first market. If approved, it could become the first new drug for the condition in 50 years.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.